In these last guidelines, for the first time, joint scientific societies have officially integrated the results of the POLE molecular test and p53 and MMR immunohistochemistry with the stage, grade, and histological type of endometrial carcinoma, as well as with the presence of LVSI in defining risk categories for endometrial cancer [14]. The gene discussed is TP53; the disease is endometrial carcinoma.